Evaluation of Sacituzumab Tirumotecan, Lenvatinib, and Pembrolizumab in Advanced Esophageal Squamous Cell Carcinoma Post PD-1/PD-L1 Therapy
- Trial ID
- 2023-505189-26-00
- Protocol
- MK-3475-06B
- Sponsor
- Merck Sharp & Dohme LLC
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to evaluate the **safety** and tolerability of combination treatments in participants with advanced esophageal squamous cell carcinoma, particularly those treatments that have not been previously evaluated in separate studies. Additionally, the study aims to estimate the objective response rate (ORR) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). These objectives are clinically relevant as they provide critical insights into the potential therapeutic benefits and risks associated with novel treatment combinations, which is essential for advancing treatment options for this patient population.
Secondary objectives include: - Evaluating progression-free survival (PFS) as assessed by BICR per RECIST 1.1. - Evaluating the duration of response (DOR) as assessed by BICR per RECIST 1.1. - Evaluating overall survival (OS). - Evaluating the safety and tolerability of investigational treatment combinations based on the proportion of participants with adverse events (AEs).
Participants
The clinical trial involves a total of **68 participants** diagnosed with **advanced esophageal squamous cell carcinoma**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. Participants were selected based on a histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable esophageal squamous cell carcinoma. They must have experienced disease progression on a prior line of standard therapy, including a platinum agent and previous exposure to an anti-programmed cell death 1 (PD1)/programmed cell death ligand 1 (PD-L1) based therapy. The trial does not include a vulnerable population. Participants are required to have adequately controlled blood pressure, with or without antihypertensive medications, and must have recovered from adverse events due to previous anticancer therapies to ≤Grade 1 or baseline. The trial does not specify any particular lifestyle considerations such as diet or physical activity. Key inclusion criteria include having an evaluable baseline tumor sample for analysis. The trial aims to evaluate the safety and tolerability of combination treatments and estimate the objective response rate as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
Plans and Procedures
The clinical trial is designed to evaluate the safety and efficacy of investigational agents, with or without **pembrolizumab** and/or chemotherapy, in participants with advanced esophageal squamous cell carcinoma. This study follows a **randomized**, open-label, umbrella platform design, and is structured into two phases: a safety lead-in phase and an efficacy phase. The trial is expected to commence recruitment on February 18, 2024, and conclude by September 20, 2028. Participants will be involved in the study for the duration of their treatment cycles, with the possibility of early termination if they experience dose-limiting toxicities or adverse events that necessitate discontinuation of the study treatment.
Study visits are sequenced to ensure comprehensive monitoring and data collection. The inclusion visit, or screening, will confirm eligibility based on criteria such as a histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable esophageal squamous cell carcinoma, prior exposure to PD-1/PD-L1 therapy, and controlled blood pressure. Participants will then proceed to the safety lead-in phase, where the primary endpoints include the number of participants experiencing dose-limiting toxicities and adverse events. Follow-up visits will assess the objective response rate, progression-free survival, duration of response, and overall survival. The end-of-study visit will finalize data collection and assess long-term outcomes.
Participants are expected to remain in the study until disease progression, unacceptable toxicity, or withdrawal of consent. Conditions leading to early termination include significant adverse events or failure to adhere to study protocols. The trial aims to provide valuable insights into the safety and efficacy of combination therapies in treating advanced esophageal squamous cell carcinoma, contributing to the development of more effective treatment regimens.
Treatment
The clinical trial involves the administration of several investigational and non-investigational agents. **MK-2870**, also known as **sacituzumab tirumotecan**, is a **powder for solution for injection**. It is administered via **intravenous use**. This biological agent is a humanized IgG1 monoclonal antibody against TROP2, conjugated to KL610023. The dosing schedule and frequency are determined based on the study protocol, and participant compliance is monitored through regular assessments.
**Lenvatinib** is provided in **capsule** form and is administered **orally**. This chemical agent is used as a test product in the trial. The dosing schedule is specified in the study protocol, and adherence is monitored through participant self-reporting and pill counts.
**MK-4830** is a **concentrate and solvent for concentrate for solution for infusion**, administered via **intravenous use**. This biological agent is included as a test product in the study. The administration schedule is outlined in the protocol, with compliance monitored through infusion records.
**KEYTRUDA 25 mg/mL concentrate for solution for infusion**, containing **pembrolizumab**, is administered via **intravenous use**. This biological agent is used as a test product, with dosing and administration details provided in the study protocol. Compliance is tracked through infusion logs and participant monitoring.
**IRINOTECAN**, a chemical agent, is administered as a **PHF00230MIG** form via **intravenous use**. It serves as a comparator treatment in the trial. The dosing regimen is specified in the protocol, and compliance is monitored through infusion records and participant assessments.
**FAMOTIDINE** is administered in **PHF00009MIG** form **orally**. This chemical agent is used as an auxiliary treatment in the study. The dosing schedule is outlined in the protocol, with adherence monitored through participant self-reporting and pill counts.
**PACLITAXEL** is provided in **PHF00230MIG** form and administered via **intravenous use**. This chemical agent is used as a test product in the trial. The administration schedule is detailed in the protocol, with compliance monitored through infusion records and participant evaluations.
Additional non-experimental treatments include **antihistamines for systemic use** and **glucocorticoids**, both administered **orally**. These chemical agents are used as auxiliary treatments, with dosing and administration details specified in the study protocol. Compliance is monitored through participant self-reporting and medication logs.
Efficacy
The efficacy of the investigational agents in the clinical trial will be assessed using several primary and secondary endpoints. The primary endpoints include the **Objective Response Rate (ORR)**, which will be evaluated by a blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). Additionally, the number of participants experiencing dose-limiting toxicities (DLTs), adverse events (AEs), and those who discontinue study treatment due to an AE during the safety lead-in phase will be recorded.
Secondary endpoints for efficacy assessment include **Progression-Free Survival (PFS)**, **Duration of Response (DOR)**, and **Overall Survival (OS)**. The trial will also monitor the number of participants experiencing at least one adverse event and those who discontinue study treatment due to an AE during the efficacy phase. These parameters will be measured and analyzed at various timepoints throughout the study to determine the efficacy of the treatment regimens in participants with advanced esophageal cancer previously exposed to PD-1/PD-L1 treatment.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable esophageal squamous cell carcinoma (ESCC).
- Has experienced investigator documented radiographic or clinical disease progression on one prior line of standard therapy, that includes a platinum agent and previous exposure to an anti-programmed cell death 1 (PD1)/programmed cell death ligand 1 (PD-L1) based immuneoncology (IO) therapy.
- Has provided an archival or most recent tumor tissue sample obtained as part of clinical practice.
- Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible.
Exclusion Criteria
- Direct invasion into adjacent organs such as the aorta or trachea.
- Has experienced weight loss >10% over approximately 2 months prior to first dose of study therapy.
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
- Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
- Known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that has undergone potentially curative therapy.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Participants with human immunodeficiency virus (HIV) with a history of Kaposi’s sarcoma and/or Multicentric Castleman’s Disease.
- History of allogenic tissue/solid organ transplant.
- Clinically significant cardiovascular disease within 12 months from first dose of study intervention.
- Has risk for significant GI bleeding such as a serious nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to allocation/randomization, significant bleeding disorders, vasculitis, or has had a significant bleeding episode from the GI tract within 12 weeks prior to allocation/randomization.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Germany | Recruiting | 18 Feb 2024 | 5 |
Italy | Recruiting | 18 Feb 2024 | 4 |
Norway | Recruiting | 18 Feb 2024 | 1 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
MK-2870 | Test | SOLUTION FOR INJECTION | INTRAVENOUS USE | — | — | PRD12802980 |
Lenvatinib | Test | CAPSULE | ORAL | — | — | PRD9414231 |
PACLITAXEL | Test | PHF00230MIG | INTRAVENOUS USE | — | — | SCP129816 |
KEYTRUDA 25 mg/mL concentrate for solution for infusion | Test | CONCENTRATE FOR SOLUTION FOR INFUSION | INTRAVENOUS USE | — | — | PRD4323105 |
FAMOTIDINE | Other | PHF00009MIG | ORAL | — | — | SCP127871 |
MK-2870 | Test | SOLUTION FOR INJECTION | INTRAVENOUS USE | — | — | PRD11447874 |
MK-4830 | Test | CONCENTRATE AND SOLVENT FOR CONCENTRATE FOR SOLUTION FOR INFUSION | INTRAVENOUS USE | — | — | PRD11040309 |
IRINOTECAN | Test | PHF00230MIG | INTRAVENOUS USE | — | — | SCP105621456 |
- | Other | PHF00245MIG | ORAL | — | — | R06A |
Lenvatinib | Test | CAPSULE | ORAL | — | — | PRD9414230 |



